Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYNTECH, INC.	-.--%	-.--%	-	-	1.16T
LONZA GROUP AG	+0.62%	-0.08%	-12.15%	-13.39%	4.27TCr
REVOLUTION MEDICINES, INC.	+3.31%	+9.22%	+308.19%	+562.02%	3.47TCr
BEONE MEDICINES AG	+2.84%	+3.80%	+6.87%	+34.93%	3TCr
IQVIA HOLDINGS INC.	-1.70%	-7.34%	+8.51%	-22.34%	2.8TCr
CELLTRION, INC.	-0.57%	+4.45%	+12.31%	+20.42%	2.48TCr
ASCENDIS PHARMA A/S	-0.14%	+7.06%	-	-	1.43TCr
MEDPACE HOLDINGS, INC.	+0.68%	-3.13%	+52.04%	+107.47%	1.31TCr
EUROFINS SCIENTIFIC SE	+0.38%	-1.53%	+6.16%	+5.17%	1.26TCr
IONIS PHARMACEUTICALS, INC.	-0.26%	+0.41%	+100.27%	+80.69%	1.22TCr
Average	+0.51%	+0.89%	+60.27%	+96.87%	2.36TCr
Weighted average by Cap.	+0.81%	+1.27%	+65.06%	+112.47%

See all sector performances

BioSyntech, Inc. is a Canada-based biotechnology company. The Company is developing biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. The Company's platform technology is a family of hydrogels called BST-Gel, some of which are liquid at low temperature and solid at human body temperature. These gels can be injected or applied to a specific local site and offers properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds and provide the benefit of avoiding invasive surgery. The Company's lead, late-stage product, BST-CarGel is undergoing an international pivotal trial.

Employees

Sector

Biotechnology & Medical Research

More about the company